What is the recommended evaluation and management for recurrence of Langerhans cell histiocytosis presenting as scalp skin lesions in a 28‑year‑old adult?

Management of Recurrent Langerhans Cell Histiocytosis with Scalp Skin Manifestations in a 28-Year-Old Adult

For a 28-year-old with recurrent LCH presenting as scalp skin lesions, perform comprehensive staging with PET-CT imaging to determine disease extent, obtain tissue confirmation with CD1a/CD207 immunostaining, and initiate systemic therapy with cladribine or cytarabine as first-line treatment if multifocal or multisystem disease is confirmed. 1

Initial Diagnostic Evaluation

Tissue Confirmation

• Biopsy the scalp lesion with immunohistochemical staining for CD1a and Langerin (CD207), which are definitive markers for LCH diagnosis 2
• The presence of CD1a-positive/CD207-positive histiocytes with inflammatory infiltrate confirms the diagnosis 3

Comprehensive Staging Workup

Use 18F-FDG PET-CT as the preferred imaging modality for staging and assessing disease extent 1. This is critical because:

• Scalp/skull lesions occur in 75% of head and neck LCH cases and frequently demonstrate CNS risk involvement 4
• Adult cutaneous LCH has a concerning association with extracutaneous disease and second hematological malignancies 5
• Multisystem disease significantly impacts treatment decisions and prognosis 1, 6

Specific staging investigations should include:

• Complete blood count, liver function tests, and metabolic panel to assess organ involvement 1
• Chest imaging to evaluate for pulmonary involvement (particularly important given the association with smoking in adults) 2
• Bone marrow evaluation if cytopenias are present 6
• Screen for diabetes insipidus with serum and urine osmolality if pituitary involvement is suspected 6

Treatment Algorithm Based on Disease Extent

For Isolated Cutaneous/Unifocal Disease

• Wide local excision may be curative for truly isolated lesions 7
• However, given this is a recurrence, isolated disease is less likely and systemic therapy should be strongly considered 1

For Multifocal or Multisystem Disease (Most Likely Scenario)

First-line systemic therapy options include: 1

1. Cladribine (2.1-5 mg/m² per day for 5 days every 28 days for 6 months) - preferred agent with documented efficacy in adult LCH 2, 1

2. Cytarabine - alternative first-line option with comparable efficacy 1

3. Emerging targeted therapies should be considered, particularly if BRAF-V600E mutation is detected:

   • BRAF inhibitors (vemurafenib, dabrafenib) for BRAF-V600E mutant disease 1
   • MEK inhibitors (cobimetinib, trametinib) for BRAF wild-type or as alternative 1

Critical Pitfall: Association with Second Hematological Malignancies

Adults with cutaneous LCH have a significantly increased risk of developing second hematological malignancies, including myelodysplastic syndrome, acute leukemia, and lymphomas 5, 8. In one series, 5 of 18 adult patients with cutaneous LCH developed a second hematological malignancy 5. This mandates:

• Long-term hematologic surveillance with periodic complete blood counts 5
• Low threshold for bone marrow evaluation if cytopenias develop 5
• Awareness that concomitant hematological malignancies may be present at diagnosis 8

Response Assessment and Surveillance

Perform first response assessment within 4 months of initiating systemic therapy 2. If disease stabilizes or achieves remission:

• Extend surveillance intervals to 6-12 months 2
• Continue monitoring for at least 5 years given high relapse rates 4
• Relapse is most likely within the first year after treatment (median 11.4 months), requiring close monitoring during this period 4

High-Risk Features for Relapse

Patients with the following characteristics have higher relapse rates and warrant more intensive surveillance 4:

• Multisystem disease involvement (71% relapse rate) 4
• Temporal bone lesions (57% relapse rate) 4
• Delay in diagnosis ≥60 days (78% of relapsed patients had diagnostic delay) 4

Management of Refractory or Relapsed Disease

If disease relapses or is refractory to first-line therapy:

• Salvage chemotherapy with cladribine or cytarabine can achieve complete remission 4
• Consider targeted therapy with BRAF/MEK inhibitors if not previously used and mutations are present 1
• Evaluate for clinical trials investigating novel agents 1, 3

Smoking Cessation

If the patient smokes, immediate smoking cessation is mandatory, as tobacco smoking is strongly associated with pulmonary LCH and may influence disease behavior 2. The cessation of smoking is considered a primary intervention in pulmonary LCH 2.

Symptom Management

Address the high symptom burden commonly experienced by adult LCH patients, including pain, fatigue, and mood disorders, which significantly impact quality of life even when disease is controlled 1. These symptoms require proactive management alongside disease-directed therapy.